Unveiling BioMarin (BMRN) Q4 Outlook: Wall Street Estimates for Key Metrics

The upcoming report from BioMarin Pharmaceutical (BMRN) is expected to reveal quarterly earnings of $0.73 per share, indicating an increase of 49% compared to the year-ago period. Analysts forecast revenues of $711.93 million, representing an increase of 10.2% year over year.Over the last 30 days, there has been a downward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts o ...